Bayer to support DNDi on oral drug development for river blindness

Bayer HealthCare has agreed to provide the ingredient emodepside to support Drugs for Neglected Diseases initiative (DNDi) in its effort to develop a new oral drug to treat river blindness, also known as onchocerciasis.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news